688075 Assure Tech
- 34.28
- +0.84+2.51%
Assure Tech News
What Assure Tech (Hangzhou) Co., Ltd.'s (SHSE:688075) P/E Is Not Telling You
Anxu Bio (688075.SH): Over 90% of the company's sales in overseas markets in 2023.
On July 8th, Gelon Hui announced that Anxu Biology (688075.SH) stated on the investor interaction platform that the company's sales model is mainly focused on overseas sales, and overseas market sales will account for more than 90% of the company's total sales in 2023.
Anxu Bio (688075.SH) will distribute a cash dividend of 0.4 yuan per share for the year 2023 on July 9th.
Anxu Bio (688075.SH) announced that it will distribute the 2023 annual cash dividend on July 9, 2024 ...
Assure Tech (Hangzhou) (SHSE:688075) Could Be Struggling To Allocate Capital
Anxu Biotech (688075.SH): Net profit in 2023 fell 95.34% year on year
Gelonghui, Feb. 28, 丨 An Xu Biotech (688075.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 508.2998 million yuan, a decrease of 91.76% over the same period of the previous year; realized net profit attributable to owners of the parent company of 141.7741 million yuan, a decrease of 95.34% over the same period last year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 52.44,800 yuan, a decrease of 98.24% from the same period last year.
Insiders Are the Top Stockholders in Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075), and the Recent 13% Drop Might Have Disappointed Them
Anxu Biotech (688075.SH): 2023 net profit pre-reduced by 94.98% to 95.82%
Gelonghui, January 30丨An Xu Biotech (688075.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve net profit of 127.3982 million yuan to 152.887 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease by 2891.754 million yuan to 2917.2751 million yuan, a year-on-year decrease of 94.98% to 95.82%. Net profit attributable to the owner of the parent company after deducting non-recurring profit and loss is expected to be 5,209.31 in 2023
[BT Financial Report Instantaneous Analysis] Anxu Biotech's 2023 Quarterly Report: Business Adjustments and Challenges Amidst Changes in Market Demand
Anxu Biotech (stock code: 688075) is a high-tech enterprise that is deeply involved in the field of POCT (instant diagnosis technology), focusing on R&D, production and sales of POCT reagents and instruments. Based on self-developed biomaterials, the company has built a diagnostic technology platform covering various fields such as drugs, infectious diseases, and chronic diseases, and has successfully sold its products to more than 150 countries around the world, becoming one of the Chinese suppliers that can compete with multinational in vitro diagnostic giants in the international market. Anxu Biotech adheres to the business principles of “fixing production by sales”, “determining procurement by production”, “moderate preparation”, and “quality is king”, and has formed
Anxu Biotech (688075.SH) will list 1,278,800 restricted shares for circulation on November 20
Anxu Biotech (688075.SH) announced that the number of strategically placed shares currently listed and distributed by the company is 127.0...
Anxu Biotech (688075.SH): Net profit for the first three quarters was 187 million yuan, a year-on-year decrease of 94.03%
On October 30, Gelonghui Biotech (688075.SH) disclosed its report for the third quarter of 2023. In the first three quarters, the company achieved revenue of 316 million yuan, a year-on-year decrease of 94.84%; net profit of 187 million yuan, a year-on-year decrease of 94.03%; non-net profit of 99.13 million yuan, a year-on-year decrease of 96.81%; and basic earnings per share of 1.47 yuan.
An Xu Biotech (688075.SH) released first-half results, with net profit of 167 million yuan, down 94.20% year on year
An Xu Biotech (688075.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Chairman of an Xu Biology spoke as the representative of the 17th Hangzhou Outstanding Entrepreneur
Stick together, never forget the initial ideal and ambition Hangzhou, April 15, 2022 / PR Newswire /-recently, the sixth and third general meetings of Hangzhou Industrial Economic Federation, Municipal Enterprise Federation and Municipal Entrepreneur Association were successfully held. Mr. Ling Shisheng, Chairman and General Manager of an Xu Biology (Stock Code: 688075), was honored as "17th Hangzhou Outstanding Entrepreneur". And spoke as an entrepreneur representative. Ling Shisheng said that winning the title of "17th Hangzhou Outstanding Entrepreneur" is a full affirmation and encouragement to his entrepreneurship for more than a decade. Anxu Biology is a research and development company.
The medical device sector fell, and 688606.CN fell 20.0%.
[Caihua Social News] at midday today, as of 13:15, the medical device plate fell. 688606.CN fell 20.00% to 175.84 yuan, 688075.CN fell 17.50% to 232.64 yuan, 688767.CN fell 16.69% to 102.06 yuan, 688068.CN fell 15.71% to 176.0 yuan, 688575.CN fell 14.33% to 38.98 yuan, 300482.CN fell 13.5%
The medical device sector opened lower, and 688606.CN fell 9.46%.
[Caihua Social News] in early trading today, as of 09:30, the medical device plate opened lower. 688606.CN fell 9.46% to 199.0 yuan, 688317.CN fell 6.98% to 62.51 yuan, 688068.CN fell 6.61% to 195.0 yuan, 002932.CN fell 6.31% to 105.63 yuan, 300439.CN fell 6.25% to 26.72 yuan, 300396.CN fell 6.20% to 19.0
The medical device sector fell, with 688399.CN down 19.16%.
[Caihua Social News] at midday today, as of 14:45, the medical device plate fell. 688399.CN fell 19.16% to 173.15 yuan, 688298.CN fell 17.08% to 341.31 yuan, 688767.CN fell 16.55% to 121.0 yuan, 688068.CN fell 14.05% to 205.97 yuan, 688075.CN fell 12.47% to 265.0 yuan, 300482.CN fell 12.
[foreign stocks] the in vitro diagnostic plate fell, and 688767.CN fell 10.62%.
[Caihua Social News] in early trading today, as of 10:00, the in vitro diagnostic plate fell. 688767.CN fell 10.62% to 129.6 yuan, 688317.CN fell 10.33% to 66.99 yuan, 688399.CN fell 10.33% to 192.07 yuan, 688575.CN fell 9.15% to 45.2 yuan, 688075.CN fell 8.60% to 276.71 yuan, 688389.CN fell 8.03% to 22.
January 14 Anxu biological limit analysis: in vitro diagnosis, COVID-19 detection, medical device concept hot stock
An Xu Biological rose and closed with a closing price of 302.76 yuan. The stock rose by the daily limit at 13:02 and opened once, with a closing fund of 436900 yuan, accounting for 0.01 per cent of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 48.3699 million yuan, the net inflow of hot capital was 64.5247 million yuan, and the net outflow of retail funds was 3.2493 million yuan. In the past 5 days, the capital flow is shown in the following table: the unit is in vitro diagnosis, COVID-19 testing, medical device concept hot stock, the same day in vitro diagnosis concept rose 5.86%, COVID-19 detection concept rose 5.7%, medical device concept rose
[foreign movement stock] in vitro diagnostic plate pulled up, 688606.CN (Aotai Bio) rose 20.0%
[Caihua Social News] by midday today, as of 13:15, the in vitro diagnostic plate was up. 688606.CN rose 20.00% to 228.0 yuan, 688075.CN rose 20.00% to 302.76 yuan, 688298.CN rose 20.00% to 411.62 yuan, 688068.CN rose 17.67% to 234.98 yuan, 688389.CN rose 14.97% to 25.58 yuan, 688767.CN rose 14.
[focus] the limit goes up for four days in a row! The share price of 688075.SH has more than tripled since its listing.
COVID-19 detection plate continues to be detonated! Since January 6, 688075.SH has risen by 20% for four consecutive days. On January 12, the company's share price continued to rise 4.98% and continued to rise high, with an overall increase of 117% in five days. As a secondary new stock of Science and Technology Innovation Board, since its listing in November last year, the stock price has risen by more than 200% in less than 2 months, making it the prettiest son of Science and Technology Innovation Board and the leader of COVID-19 testing plate. The performance of COVID-19 testing plate has greatly increased, and funds have poured into the news. Recently, there has been a high incidence of epidemics in many places around the world, and recently overseas.
January 11 Anxu biological limit analysis: COVID-19 detection, in vitro diagnosis, medical device concept hot stock
An Xu Biological rose and closed with a closing price of 257.2 yuan. The stock rose by the limit at 13:08 and opened the limit four times. The closing capital was 1.3295 million yuan, accounting for 0.04% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 36.1841 million yuan, the net inflow of hot capital was 65.2318 million yuan, and the net outflow of retail funds was 3.2375 million yuan. In the past 5 days, the capital flow is shown in the following table: this unit is COVID-19 testing, in vitro diagnosis, medical device concept hot stock. On the same day, COVID-19 detection concept rose 1.67%, in vitro diagnosis concept rose 1.48%, medical device concept
Analysis
Price Target
No Data
